SECOVID: A Multi-center, Randomized, Dose-ranging Parallel-group Trial Assessing the Efficacy of Sirolimus in Hospitalized Patients With COVID-19 Pneumonia for the Prevention of Post-COVID Fibrosis
Latest Information Update: 05 Aug 2024
Price :
$35 *
At a glance
- Drugs Sirolimus (Primary)
- Indications Pulmonary fibrosis
- Focus Therapeutic Use
- Acronyms SECOVID
- 01 Aug 2024 Planned End Date changed from 1 Jun 2024 to 1 Dec 2025.
- 01 Aug 2024 Planned primary completion date changed from 1 Jun 2024 to 1 Dec 2025.
- 18 Nov 2022 Planned End Date changed from 1 Jun 2022 to 1 Jun 2024.